Author:
Nakai Y,Isayama H,Ijichi H,Sasaki T,Sasahira N,Hirano K,Kogure H,Kawakubo K,Yagioka H,Yashima Y,Mizuno S,Yamamoto K,Arizumi T,Togawa O,Matsubara S,Tsujino T,Tateishi K,Tada M,Omata M,Koike K
Publisher
Springer Science and Business Media LLC
Reference34 articles.
1. Ager EI, Neo J, Christophi C (2008) The renin-angiotensin system and malignancy. Carcinogenesis 29 (9): 1675–1684
2. Amaya K, Ohta T, Kitagawa H, Kayahara M, Takamura H, Fujimura T, Nishimura G, Shimizu K, Miwa K (2004) Angiotensin II activates MAP kinase and NF-kappaB through angiotensin II type I receptor in human pancreatic cancer cells. Int J Oncol 25 (4): 849–856
3. Arafat HA, Gong Q, Chipitsyna G, Rizvi A, Saa CT, Yeo CJ (2007) Antihypertensives as novel antineoplastics: angiotensin-I-converting enzyme inhibitors and angiotensin II type 1 receptor blockers in pancreatic ductal adenocarcinoma. J Am Coll Surg 204 (5): 996–1005; discussion 1005–1006
4. Berlin JD, Catalano P, Thomas JP, Kugler JW, Haller DG, Benson III AB (2002) Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol 20 (15): 3270–3275
5. Burris III H, Rocha-Lima C (2008) New therapeutic directions for advanced pancreatic cancer: targeting the epidermal growth factor and vascular endothelial growth factor pathways. Oncologist 13 (3): 289–298
Cited by
146 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献